Objective: To demonstrate the clinical spectrum and challenges associated with clinical management of epitheloid angiomyolipomas (eAML).
Methods: We retrospectively reviewed the surgical database of a high-volume tertiary kidney cancer center from 2015 to 2020 to identify cases with a final histological diagnosis of eAML. Descriptive analysis of all cases was conducted.
Results: Five surgical cases of eAMLs were identified. Two of which have had no tumor recurrence since surgery, and three patients passed away due to disease progression.
Conclusion: eAML are rare renal tumors which the World Health Organisation (5th Edition, 2022) and International Classification of Diseases for Oncology classify as having unspecified, borderline, or uncertain behavior. Here, we report that can also demonstrate aggressive behavior with fatal consequences. Post-operative follow-up should be recommended for all, with shorter intervals for patients with poor prognostic factors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.urology.2023.03.017 | DOI Listing |
Am J Case Rep
December 2024
Department of Pathology, Eskişehir City Hospital, Eskişehir, Turkey.
BACKGROUND Perivascular epitheloid cell neoplasm (PEComa) is a rare mesenchymal tumor that is evaluated in the same tumor family as angiomyolipoma, sugar cell tumor of the lung, and lymphangioleiomyomatosis. Immunohistochemically, the disease can express melanocytic and myogenic markers, such as HMB45, HMSA1, MelanA/Mart1, and actin. The disease can be seen in almost every organ, especially the uterus and retroperitoneum.
View Article and Find Full Text PDFUrology
June 2023
UCL Division of Surgery and Interventional Science, London, United Kingdom; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, United Kingdom.
Objective: To demonstrate the clinical spectrum and challenges associated with clinical management of epitheloid angiomyolipomas (eAML).
Methods: We retrospectively reviewed the surgical database of a high-volume tertiary kidney cancer center from 2015 to 2020 to identify cases with a final histological diagnosis of eAML. Descriptive analysis of all cases was conducted.
Urologe A
February 2022
Carl-Thiem-Klinikum Cottbus, Thiemstraße 111, 03048, Cottbus, Deutschland.
Background: Therapy of epitheloid angiomyolipomas (eAML) may be challenging, since unlike classical angiomyolipomas this rare subclass of benign mesenchymal angiomyolipomas may present with lymph node metastases, local recurrent disease, and/or systemic metastatic disease in up to 30% of cases.
Objectives: We report here for the first time in Germany a case of eAML after successful treatment of malignant melanoma.
Materials And Methods: Clinical and histological findings as well as results of the genetic analysis of the angiomyolipoma are presented.
Pathology
January 2021
Histopathology Core Facility, Niigata University Faculty of Medicine, Niigata, Japan.
It has been 35 years since Professor Thoenes and his colleagues discovered chromophobe renal cell carcinoma (RCC). Since then, our knowledge about this tumour entity has changed and novel tumour entities have been discovered. The aim of this review is to discuss recent molecular findings and open questions in diagnosing chromophobe-like/oncocytic neoplasms.
View Article and Find Full Text PDFCurr Probl Diagn Radiol
August 2019
Department of Radiology, All India Institute of Medical Sciences (A.I.I.M.S), New Delhi, India.
Angiomyolipomas (AML) are benign tumors of the kidneys frequently encountered in radiologic practice in large tertiary centers. In comparison to renal cell carcinomas (RCC), AML are seldom treated unless they are large, undergo malignant transformation or develop complications like acute hemorrhage. The common garden triphasic (classic) AML is an easy diagnosis, however, some variants lack macroscopic fat in which case the radiologic differentiation from RCC becomes challenging.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!